Myron W. Wentz Sells 21,209 Shares of USANA Health Sciences, Inc. (USNA) Stock
USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 21,209 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $66.11, for a total transaction of $1,402,126.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of USANA Health Sciences, Inc. (NYSE USNA) traded down 1.64% during midday trading on Monday, reaching $65.90. 144,013 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $59.46 and its 200 day moving average price is $60.63. The firm has a market capitalization of $1.61 billion, a P/E ratio of 17.12 and a beta of 1.09. USANA Health Sciences, Inc. has a 52-week low of $52.55 and a 52-week high of $71.00.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.54%. The firm had revenue of $261.77 million during the quarter, compared to the consensus estimate of $259.52 million. During the same quarter in the prior year, the firm earned $2.40 EPS. USANA Health Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities research analysts anticipate that USANA Health Sciences, Inc. will post $3.87 EPS for the current fiscal year.
USANA Health Sciences announced that its board has approved a stock repurchase plan on Tuesday, July 25th that allows the company to repurchase $64.60 million in shares. This repurchase authorization allows the company to reacquire up to 46% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its position in USANA Health Sciences by 13.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock valued at $135,000 after purchasing an additional 245 shares during the last quarter. Victory Capital Management Inc. raised its position in USANA Health Sciences by 124.7% in the 1st quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock valued at $122,000 after purchasing an additional 1,175 shares during the last quarter. Creative Planning raised its position in USANA Health Sciences by 528.0% in the 2nd quarter. Creative Planning now owns 2,512 shares of the company’s stock valued at $161,000 after purchasing an additional 2,112 shares during the last quarter. SG Americas Securities LLC purchased a new stake in USANA Health Sciences in the 2nd quarter valued at $162,000. Finally, Eqis Capital Management Inc. purchased a new stake in USANA Health Sciences in the 2nd quarter valued at $210,000. Hedge funds and other institutional investors own 44.62% of the company’s stock.
USNA has been the topic of several research reports. Pivotal Research dropped their price target on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, July 26th. BidaskClub upgraded shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.